By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Development and commercialization of icosapent ethyl (VASCEPA)49.67M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
US product revenue, net166.7M72.92%
Rest of World (RoW) product revenue, net24.23M10.60%
Licensing and royalty revenue24.02M10.51%
Europe product revenue, net13.66M5.98%